Mallinckrodt Pharmaceuticals (NYSE:MNK) is reportedly considering a sale of its generic drug unit in an effort to focus its portfolio on high-margin branded drugs, according to a report from Reuters.
The divestment comes only months after the company sold its nuclear imaging business to IBA Molecular for $690 million. The sale of its generics business could bring in as much as $2 billion to the pharmaceutical company.
Get the full story at our sister site, Drug Delivery Business News.
The post Mallinckrodt mulls sale of generics biz appeared first on MassDevice.
from MassDevice http://ift.tt/2rpvDrY
Cap comentari:
Publica un comentari a l'entrada